FDA approves BMS’s Augtyro for lung cancer treatment
November 16, 2023Medical Communications FDA, Oncology, bristol myers squibb, lung cancer
Bristol Myers Squibb has announced that the US Food and Drug Administration (FDA) has approved Augtyro (repotrectinib) for the treatment …
Prange Group and Adragos Pharma to acquire Fresenius Kabi’s manufacturing site
November 16, 2023Business Services Fresenius Kabi, Pharmacy, Prange Group, acquisition
Prange Group and Adragos Pharma have announced the signing of definitive agreements with Fresenius Kabi for their acquisition of its …
Kesin Pharma’s Likmez approved by FDA
November 15, 2023Medical Communications Kesin Pharma, Likmez, Pharmacy, Saptalis Pharmaceuticals, antibiotic
Kesin Pharma has announced that the US Food and Drug Administration (FDA) has approved Likmez (metronidazole) oral suspension, 500mg/5mL, for …
Alvotech and JAMP Pharma’s Jamteki gains marketing authorisation from Health Canada
November 15, 2023Medical Communications Alvotech, Health Canada, JAMP Pharma, Pharmacy, biosimilar
Alvotech and JAMP Pharma have announced that Health Canada has granted JAMP Pharma marketing authorisation for AVT04, a biosimilar to …
Autifony announces global license and collaboration agreement with Jazz Pharmaceuticals
November 14, 2023Business Services Autifony, Neurology, collaboration, jazz pharmaceuticals, neurological disorders
Autifony Therapeutics has announced that it has entered an exclusive global licensing agreement with Jazz Pharmaceuticals for up to $770.5m, …
Health Canada approves Ipsen and Medision Pharma’s Bylvay for pruritus treatment
November 14, 2023Medical Communications Health Canada, Medision Pharma, Rare Diseases, ipsen, pruritis
Ipsen and Medision Pharma have announced that Health Canada has approved Bylvay (odevixibat) for the treatment of pruritis in patients …
Enhanc3D Genomics appoints Hazel Jones as chief operating officer
November 14, 2023Business Services Enhanc3D Genomics, Hazel Jones, chief operating officer
Enhanc3D Genomics has announced the appointment of Hazel Jones as chief operating officer. This appointment marks part of the company’s …
Anthony Johnson appointed NanoSyrinx’s non-executive director
November 14, 2023Business Services Anthony Johnson, NanoSyrinx, non-executive director
NanoSyrinx has announced the appointment of Anthony Johnson MD to its board as non-executive director. This appointment marks part of …
GSK gains positive CHMP opinion for momelotinib for myelofibrosis treatment
November 13, 2023Medical Communications CHMP, GSK, Haematology, anaemia, momelotinib, myelofibrosis
GSK has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has …
AstraZeneca’s Imfinzi meets primary endpoint for liver cancer treatment
November 13, 2023Research and Development AstraZeneca, Imfinzi, Oncology, clinical trial, liver cancer
AstraZeneca has announced positive results from the EMERALD-1 phase 3 trial for Imfinzi (durvalumab) in combination with transarterial chemoembolisation (TACE) …
Daiichi Sankyo’s Vanflyta approved by EC for acute myeloid leukaemia treatment
November 10, 2023Medical Communications Daiichi Sankyo, EC, EU, Oncology, Vanflyta, acute myeloid leukaemia
Daiichi Sankyo has announced that Vanflyta (quizartinib) has been approved in the EU for combination use with standard cytarabine and …
Novo Nordisk invests 42bn Danish kroner to expand facilities in Kalundborg, Denmark
November 10, 2023Manufacturing and Production Chronic Diseases, Denmark, Novo Nordisk, investment, manufacturing
Novo Nordisk have announced plans to invest over 42bn Danish kroner to expand its existing manufacturing facilities in Kalundbord, Denmark, …
Eli Lilly’s Zepbound approved by FDA for chronic weight management
November 9, 2023Medical Communications Eli Lilly, FDA, Obesity, Zepbound, weight loss, weight management
Eli Lilly has announced that the US Food and Drug Administration (FDA) has approved Zepbound (tirzepatide) injection for chronic weight …
First patient dosed in AdvanCell’s phase 1/2 trial for prostate cancer treatment
November 9, 2023Research and Development AdvanCell, Cancer, Oncology, clinical trial, prostate cancer
AdvanCell has announced that the first patient has been dosed with 212Pb-ADVC001 in its phase 1/2 trial for the PSMA-positive …
J&J’s to submit surgical robot to FDA in 2024
November 8, 2023Research and Development FDA, J&J, Johnson & Johnson MedTech, Pharmacy, surgical robot
Johnson & Johnson MedTech have announced plans to submit the Ottava robotic surgical system to the US Food and Drug …
Bit.bio announces cell therapy pipeline
November 8, 2023Medical Communications Hepatology, bit.bio, cell therapy, liver failure
Bit.bio has announced its cell therapy pipeline as well as having shared its lead cell therapy candidate, preparing to enter …
Halozyme and Acumen Pharmaceuticals enter collaboration for Alzheimer’s treatment
November 7, 2023Business Services Acumen Pharmaceuticals, Alzheimer's disease, Halozyme, Neurology, collaboration
Halozyme Therapeutics has announced a global collaboration and non-exclusive license with Acumen Pharmaceuticals, providing Acumen with access to Halozyme’s Enhanze …
Evotec and Dewpoint Therapeutics enter strategic partnership
November 7, 2023Research and Development Dewpoint Therapeutics, Evotec, Oncology, R&D, oncology
Evotec and Dewpoint Therapeutics have announced a strategic R&D collaboration for the advancement of Dewpoint’s oncology pipeline programmes of condensate …
Regeneron plans to share advancements from blood cancer pipeline
November 6, 2023Medical Communications ASH annual meeting, Haematology, Regeneron, blood cancer, haematology
Regeneron Pharmaceuticals have announced that it plans to share new and updated data from its haematology pipeline at the American …
AstraZeneca shares results from ZENITH-CKD phase 2b trial for chronic kidney disease and proteinuria treatment
November 6, 2023Research and Development AstraZeneca, CKD, Nephrology, kidney disease, proteinuria
AstraZeneca has announced results from the ZENITH-CKD phase 2b clinical trial for the combination of zibotentan with dapagliflozin for the …
Latest content
FibroFind appoints Lee Borthwick as CEO
